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Drug-resistant tuberculosis is quickly emerging as one of the largest threats to the global
health community. Current chemotherapy for tuberculosis dates back to the 1950s and is ar-
duous, lengthy, and remains extremely difficult to complete in many of the highest burdened
areas. This causes inadequate or incomplete treatment, resulting in genetic selection of
drug-resistant strains. With a dearth of novel anti-TB drug candidates in the development
pipeline, nanoparticle technology allows us to take current chemotherapies and deliver them
more efficaciously, reducing the frequency and duration of treatment and increasing bioavail-
ability. This approach can improve patient adherence, reduce pill burden, and shorten time
to completion, all which are at the heart of drug resistance. This review examines the mul-
tiple advantages of nanoparticle drug delivery of tuberculosis chemotherapy and summa-
rizes the challenges in implementation.
introduction
Drug resistance in Mycobacterium tu-
berculosis (Mtb†) is widely regarded as one
of the most pressing issues the medical
community faces today. Mtb infects one-
third of the world’s population, of which up
to 10 percent will develop active tubercu-
losis infection (TB) [1]. Treatment for un-
complicated, drug-susceptible TB is stren-
uous and demanding and has a complex
regimen typically requiring a minimum of
6 months of medication [2]. Subsequently,
this  results  in  incomplete  treatment  of
chemotherapy for the patient. This incom-
plete or inadequate treatment has resulted
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berculosisin the emergence of multi-drug-resistant TB
(MDR-TB) and extensively drug-resistant
tuberculosis  (XDR-TB).  MDR-TB  is  a
strain of TB that is susceptible to few first
line medications, and XDR-TB is regarded
as untreatable [3]. Both of these conditions
are expensive, preventable, and devastating
for the person infected. Aims to curb drug
resistance, such as implementation of the
World Health Organization’s DOTS pro-
gram  (Direct  Observed  Therapy,  short
course), have proven problematic and done
little to stem the rising cases of DR-TB.
While many low- and middle-income coun-
tries continue to be plagued with a lack of
capacity, the world simply cannot afford to
allow the DR-TB epidemics to continue on
their current trajectory [4]. 
Nanoparticle technology, which in the
context of drug delivery can be broadly de-
fined as the creation of submicron colloidal
particles, has become an exciting advance-
ment in drug delivery [5]. However, to date,
little research has been done to elucidate the
impact this technology has on the drug-re-
sistant TB epidemic. Although the develop-
ment of novel TB drugs remains paramount
to surmounting the TB epidemic, modifying
new drugs in a nanoparticle-based delivery
system is a feasible, cost-effective, and read-
ily available alternative. Using current anti-
TB drugs, nanoparticle-based formulations
may shorten drug regimen duration, reduce
frequency, and deliver medications more ef-
ficaciously, ultimately reducing patient de-
fault and improving completion rates. In
turn, this holds significant potential in the
reduction of DR-TB cases.
Here, we look at the multiple advantages
that nanoparticle delivery of drug-susceptible
TB regimens has and its effect on stemming
the emergence of drug-resistant TB. 
M. tuberculosis, current
treAtMents, And resistAnce
A  multifarious  treatment  for  TB  is
needed due to the particularly tenacious and
diverse cell wall of Mtb. This highly com-
plex cell wall is fundamental in the patho-
genesis  of  Mtb,  controlling  the  growth,
survival, and the host immunological re-
sponse.  The  cell  wall  is  unique  among
prokaryotes, and its structure has been well-
defined in previous literature [6-8]. Briefly,
it consists of a layer of peptidoglycan sur-
rounding the cell’s basic lipid bilayer. A sec-
ond layer of arabinogalactin runs parallel to
the peptidoglycan layer, surrounding it in an
intricate, sugary shell. A third layer extends
perpendicular to the arabinogalactin shell
and consists of a complex network of my-
colic acids. These long and “sticky” mycolic
acids are tightly bound in a final exterior
layer, rendering the bacilli virtually imper-
meable and almost entirely waterproof. This
complex armor allows Mtb to be resistant to
many antibiotics, avoid death by acidic and
alkaline compounds, and prevent cellular
phagolysosomal fusion, allowing it to suc-
cessfully evade lysis. Figure 1 depicts a sim-
ple visual representation of the Mtb cell
wall.
These properties make current treat-
ment for active drug-susceptible TB infec-
tion  particularly  arduous;  typically  a
6-month regimen consisting of a 2-month
“intensive” phase of rifampicin (RMP), iso-
niazid  (INH),  pyrazinamide  (PZA),  and
ethambutol (EMB) given 7 times per week,
followed by a 4-month continuation phase
of RMP and INH given 3 times a week [2].
INH, a prodrug activated by the cata-
laserperoxidase (KatG) enzyme, is the most
well-known and used drug to treat TB [9].
Though the activation produces several re-
active species that play multiple roles in
treating the bacilli, including both reactive
oxygen  (superoxides,  peroxides)  and  or-
ganic (isonicotinic-acyl) species, the pri-
mary target of INH is thought to be the
enoyl-acyl carrier protein reductase enzyme,
which plays a role in the synthesis and elon-
gation of mycolic acids on the cell exterior
[10-12]. The bactericidal RMP binds to the
ʲ-subunit of the RNA polymerase upstream
of the catalytic center and prevents the for-
mation of the RNA chain [9]. PZA is a pro-
drug converted into pyrazinoic acid (POA)
by the pyrazinamidase enzyme [13]. The
protonated POA accumulates in the cell and
causes cytoplasimic acidification and re-
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proton motive force and affecting membrane
transport [14]. EMB is a bacteriostatic agent
that inhibits the polymerization of arabinan,
arabinogalactan,  and  lipoarabinomannan,
thus preventing its biogenesis formation on
the cell wall [15]. Drug resistance in M. tu-
berculosis is due to spontaneous chromoso-
mal  mutations  and  is  worsened  by  the
absence or inefficiency of resistance-medi-
ating genetic elements such as transposons
and plasmids [16,17].
Drug resistance in TB is a direct off-
spring  of  incomplete  or  inadequate  drug
treatment regimens; inadequate treatment of
TB regimens often only acts on drug-sus-
ceptible  strains,  allowing  drug-resistant
species to survive and amplify. Multi drug-
resistant TB (MDR-TB) is defined as active
tuberculosis disease that is resistant in vitro
to the two most highly effective drugs to
treat TB ― rifampicin and isoniazid ― with
or without resistance to other drugs. Treat-
ment requires the use of several harsh sec-
ond-line drugs, including injectables such as
capreomycin,  kanamycin,  and  amikacin.
These drugs have a wide range of severe and
chronic side effects, including hearing loss,
diarrhea, depression, abdominal pain and
nausea, neurapathy, and fatigue [18]. Treat-
ment typically lasts 24 to 27 months and is
25 to 50 times more expensive to treat. Ex-
tensively drug-resistant TB (XDR-TB) can
be defined as resistance to INH and RMP in
vitro,  any  of  the  second-line  fluoro-
quinolones, and one or more of the second-
line injectable drugs. There is no consensus
on treatment regimen, and XDR-TB is gen-
erally considered untreatable [3].
Historically, drug resistance in TB is a re-
sult of endogenous re-infection, in which in-
complete treatment allows for the genetic
selection of resistant TB strains. Incomplete
treatment may be a result of patient default,
inadequate drug supply, or improper diagnosis
and is largely perpetuated by poor TB health
programs and infrastructures. However, recent
evidence has shown that MDR-TB is now
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Figure 1. Basic structure of M. tuberculosis cell wall. The cell wall of Mtb is comprised
of four layers, making treatment difficult and complex. The outer layer of mycolic acids sur-
rounds inner layers of arabinogalactin and peptidoglycan. These surround the traditional
phospholipid bilayer of the cell.being transmitted exogenously, and a growing
proportion of MDR-TB cases are now pri-
mary acquired infections [19]. This poses a
significant threat to health infrastructures, par-
ticularly communities living in squalid living
conditions with poor infection control.
The scientific community has long been
aware of nanoparticle delivery of anti-tuber-
culosis drugs, yet virtually no literature has
highlighted the impact that this technology
has on stemming the pressing drug-resistant
TB epidemic we face today [20,21]. Nanopar-
ticle-based drug delivery of drug susceptible
TB can shorten treatment duration, reduce fre-
quency, and improve treatment outcomes of
current therapies, all of which certainly strike
at the heart of drug resistance.
BrieF overview oF nAnoPArticles
in drug delivery
“Nanoparticle”  is  a  broad  term  that
refers to a colloidal particle with a size of
less than 1 micron (<1µm) [5]. They can be
made from a wide array of biocompatible
materials, including natural substances such
as  alginate  and  albumin,  synthetic  sub-
stances such as polylactides, or solid lipids.
Table 1 shows a list of common polymeric
carriers used in nanoparticle drug delivery
[22]. Depending on the drug delivery design
and matrix composition, nanoparticles will
either take the form of monolithic nanopar-
ticles  (nanospheres)  or  nanocapsules.
Nanospheres embed the drug in the poly-
meric matrix, whereas nanocapsules confine
the  drug  within  a  hydrophobic  or  hy-
drophilic core surrounded by a definitive
“capsule” [5].
This  incredible  breadth  of  diversity
among  nanoparticle  function  has  proven
successful in a wide variety of treatments,
including multiple cancer chemotherapies,
ARVs, and even suntan lotion [23-25]. In the
context of tuberculosis, it provides signifi-
cant advantage; among the many advantages
are  increased  carrier  capacity,  reduced
degradation in the bowels, improved stabil-
ity, and the ability to cater to both a hy-
drophobic  and  hydrophilic  environment.
Improved technological versatility also al-
lows for the targeting of nanoparticles to
specific cellular processes, affords for the
controlled release of medication, and a tai-
lors a specific pharmokenetic profile [22].
AdvAntAges in nAnoPArticle
delivery in drug-suscePtiBle
tB drugs
Advantageous Modes of Drug 
Administration Using Nanoparticle 
Delivery
Due to the size and versatility of the
nanoparticles, drug administration has ad-
vantages over standard techniques. Given the
wide  variety  of  polymers  researched  and
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natural carriers
Proteins and Polypeptides
Albumin
Fibrinogen, fibrin
Collagen
Gelatin
Casein
Polysaccharides
Alginic Acid
Starch
Dextrans, dextrin
Hydaluronic Acid
Chitin
Chitosan
table 1. common compounds in nanoparticle drug delivery [22]
synthetic carrriers
Alipatic polyesters and hydroxy acids
Polyactic Acid
Polyglycolic Acid
Poly(lactide-co-glycolide)
Poly(hydroxybutyric acid)
Polycaprolactone
Polyanhydrides
Polyorthoesters
Poly(alkylcyanoacrylate)
Polyamino acids
Polyacrylamides
Poly(alkylcarbonates)available  for  use  with  tuberculosis
chemotherapy, routes of administration in-
clude oral, intravenous, subcutaneous, and in-
halable. In contrast to current oral drugs, oral
delivery of nanoparticle-encapsulated anti-tu-
berculosis drugs (ATDs) such as poly-(DL-
lactide-co-glycolide)  (PLG)  nanocapsules
have been commonly shown to increase effi-
cacy of the administered drugs, reduce degra-
dation in the bowels, and increase uptake and
bioavailability  [26,27].  The  size  of  the
nanoparticle allows for increased transcyto-
sis in the gut lumen’s M cells, facilitated in-
tracellular uptake in the lining epithelium,
and improved uptake in the Peyer’s patch
[28-30]. This significantly reduces loss of the
active anti-TB chemical in the bowels before
entering the bloodstream and radically in-
creases bioavailability.
Intravenous administration of first line
ATDs is a unique advantage only achieved
by nanoparticle technology. Upon adminis-
tration, this method directly supplies the sys-
temic bloodstream with all ATDs, in effect
resulting in absolute bioavailability [22].
Subcutaneous injection of ATD-loaded PLG
nanoparticles has also shown similarly high
bioavailability in mice [31]. Because of their
size,  injected  or  intravenous  delivery  of
nanoparticles have a superior capability of
intracapillary passage and cellular uptake,
reinforcing exceptional bioavailability [30].
Additionally, nanoparticles also have the
potential of inhalable drugs for pulmonary
TB, which is the most common form of ac-
tive tuberculosis disease. In addition to direct
delivery of the ATDs to the site of infection,
inhaled chemotherapies also do not undergo
first-pass metabolism. In addition, nanopar-
ticles are preferentially engulfed by the alve-
olar macrophage, the same immune cell that
first responds to an Mtb encounter [30]. As
Mtb is an intracellular organism, releasing
ATDs into the “lion’s den” holds significant
potential in combating the bacilli.
Sustained Delivery of ATDs Using
Nanoparticles
Regardless of delivery method, several
studies have shown that nanoparticle deliv-
ery of ATDs provides sustained release in
both blood plasma as well as organ tissue.
Pandley et al. demonstrated in mice that a
single orally administered dose of PLG na-
noencapsulated  ATDs  (RMP,  INH,  and
PZA) exhibited superior sustained release
with physiologically relevant concentrations
maintaining in the blood plasma from 4 days
(RMP) to 9 days (INH and PZA), whereas
unbound (standard) ATDs were cleared from
plasma within 12 to 24 hours. Moreover,
physiologically relevant drug concentrations
remained in tissue from 9 to 11 days [26]. In
a separate experiment, Pandley et al. also
demonstrated that when administered via
subcutaneous  injection,  a  single  dose  of
drug-loaded PLG nanoparticles resulted in
sustained therapeutic blood plasma concen-
trations for 32 days and tissue concentra-
tions for 36 days [31]. Additionally, Sung et
al. demonstrated that an inhalable dry pow-
der of porous nanoparticles containing PA-
824  (an  alternative  anti-TB  candidate)
sustained drug levels in the lungs for up to
32 hours. On the other hand, lung concen-
trations of oral administration of PA-824
were considerably less [32]. 
Targeting of Nanoparticle-Delivered ADTs
Standard delivery of first line ATDs are
orally administered once daily, and there-
fore, anti-TB agent is broadly distributed
throughout the body. Moreover, Mtb is an
intracellular organism, creating yet another
hurdle for these anti-TB agents to overcome.
The need for intracellular chemotherapy has
been recognized for many years, specifically
to the alveolar macrophage, which is a reser-
voir for Mtb bacilli [30]. Macrophages typ-
ically  exhibit  preferential  uptake  of
nanoparticles [33]. This preferential uptake
has been shown in a number of experimen-
tal models and is due to cell physiology and
the biochemical nature of the nanopolymer
[34,35]. This allows for more specific tar-
geting of the active ingredient. Anisimova et
al. demonstrate that poly(butyl cyanoacry-
late)  nanoparticles  loaded  with  INH  and
streptomycin (another anti-TB candidate) in-
creased the intracellular accumulation of
both drugs in human blood monocytes. This
is further reinforced by studies showing the
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ciprofloxacin in the infected macrophages
[36,37]. 
iMPlicAtions oF nAnoPArticle
Atd delivery on drug-resistAnt
tuBerculosis 
Though the advantages outlined above
are  applied  to  drug-susceptible TB,  they
hold significant influence in molding the fu-
ture of the ever-increasing drug-resistant TB
epidemic. Though often implied, this simple
fact neglects to be explicitly stated in rele-
vant literature. By increasing bioavailabil-
ity, obtaining sustained therapeutic plasma
and tissue concentrations and targeting dis-
creet intracellular processes, nanoparticles
provide a means of reducing treatment du-
ration, frequency, and pill burden.
Unfortunately, lethargy in global drug
discovery does not place any novel candi-
date for first-line treatment for DR-TB on
the near horizon. Therefore, the most effi-
cient method of combating DR-TB is proper
drug susceptible TB treatment, improved pa-
tient compliance, and proper infection con-
trol. Chemotherapy regimens with superior
sustained release pharmokenetic profiles,
targeted delivery, and improved bioavail-
ability can significantly reduce regimen du-
ration, dose frequency, and dose load. This
can greatly increase compliance in drug-sus-
ceptible TB patients, in turn improving cure
rates and eliminating the possibility of a
drug resistant reinfection.
However, the true effect of nanoparticle
technology can only be appreciated when
looking at the broader context of the disease.
Though these benefits are universal to TB
patients around the globe, they serve partic-
ular importance in low- and middle-income
countries  that  have  substandard  public
health infrastructures, squalid living condi-
tions,  and  poor  infection  control.  These
countries carry the majority of the global TB
burden, with rates 20 times higher than that
of high-income countries [38]. In addition to
TB, the burden of DR-TB is also relegated
to resource-constrained countries, which re-
main lacking in proper diagnostic capacity,
medical professionals, and access to health
care [18]. Additionally, patients with DR-TB
often do not have transportation, lack the ed-
ucation, and cannot afford to lose the op-
portunity cost of missing a day’s work to
make the arduous visits to health clinics. It is
in these settings that DR-TB thrives and
conversely, where nanoparticle delivery of
can make the largest impact.
Though there are no first-line MDR- or
XDR-TB  drugs,  nanoparticle  technology
also can be applied to several second line
drugs [22]. However, resistance profiles in
DR-TB vary greatly. Recently, there is a
growing body of evidence demonstrating
that increased levels of drug-susceptible TB
chemotherapy, namely high-level INH, can
be  used  to  overcome  MDR-TB  [39,40].
However, this has only been investigated in
conventional methods of drug delivery and
poses little actual potential; in other words,
if the patient defaulted treatment of a stan-
dard regimen that resulted in their MDR-TB
(regardless of reason), there is little rationale
to believe compliance to an increased regi-
men will prove successful. In this frame-
work, nanoparticle delivery of INH could
simultaneously  reduce  regimen  burden
while increasing therapeutic dosage of INH.
Though increasing drug dose to combat drug
resistance is not ideal, in limited-resource
settings this development could prove to be
life saving ― not just for the patient, but
also potentially for the patient’s family and
community by reducing the spread of the
deadly bacteria.
PotentiAl oBstAcles And 
outlook
There are several obstacles to overcome
as nanoparticle delivery of TB chemother-
apy emerges as a key mediator against both
the TB and DR-TB epidemics. Though in-
complete treatment is the crux of drug re-
sistance in TB, the cause of this disruption is
not always as evident, nor is it readily solv-
able if it were to be pronounced. Nanotech-
nology simply has the power to reduce the
burden on the patient, a feat that cannot be
overstated. However, as a disease of poverty
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opment of these drugs will not solve the is-
sues of supply, access, or education. Serious
and sustained global support to close these
health gaps is paramount to the worldwide
success of overcoming TB. Elementarily
speaking, regardless of efficacy, a drug must
be able to reach the patient in order to be ef-
fective.
Aside from these factors, nanotechnol-
ogy remains to have its own barriers to over-
come, namely the dearth of human trials for
any of the proposed methods. Additionally,
physiological barriers persist; for instance,
though  research  is  proving  successful  in
some inhalable solutions [41], the mass me-
dian aerodynamic diameter often remains
too low to allow the particle to reach the
needed areas of the lung. Issues of nebuliza-
tion and insufflation have yet to be ironed
out in many proposed models. Moreover, in-
jectable and inhalable routes of administra-
tion would require medical professionals
and supervision, which is an issue discussed
above  as  already  plaguing  current  infra-
structures. Though not all, many polymers
would need to stay at a certain temperature,
often  unfeasible  in  low-income  settings.
Quality  control  measures,  shelf  life,  and
long-term stability have yet to be resolved,
nor have issues of human toxicity and reac-
tion.  These  issues  would  appear  to  be
worked out after the establishment of human
trials. Lastly, as a less-profitable business,
summoning enough momentum among drug
companies and governments will continue
to be a hurdle in implementing nanotech-
nology to TB chemotherapy. 
However these obstacles are surmount-
able, the global health machinery remains
lethargic  in  researching  and  developing
widespread practical uses of nanotechnol-
ogy in TB and DR-TB. Serious questions re-
main as to why drug development for TB, in
any context, has seen little advance over the
past decades; the current chemotherapy reg-
imen used today predates the United States’
first moon landing. Lack of financial and po-
litical motivation, a disconnection between
the two sciences, and the enduring hope of
novel DR-TB drug candidates continue to
plague the advancement of nanotechnology
in TB chemotherapy.
Once these hurdles are overcome, only
deciding on the superior polymer remains in
question. Future research will almost cer-
tainly focus on elucidating toxicological is-
sues associated with certain polymers, such
as more specifically illuminating the fate of
the nanocarriers, degradation, and toxicol-
ogy and routes of elimination of residual
polymers. Because of this, natural polymers
offer a probable avenue for future research.
conclusion
There is no magic bullet for surmount-
ing the TB and DR-TB epidemics. However,
given our current trajectory in TB programs,
research, and drug development, there is lit-
tle reason to believe that we will turn the tide
against the rising DR-TB epidemic in the
near future. Though development of novel
TB drugs remains a priority, the scarcity of
drug candidates in the development pipeline
combined with the exponential increase of
DR-TB incidence and prevalence forces the
medical community to consider plausible al-
ternatives. Nanotechnology is this alterna-
tive:  it  takes  current  chemotherapy  and
utilizes it more efficaciously.
The primary advantages are decreased
frequency and duration of treatment via sus-
tained concentration profiles and targeted
delivery. These advantages will likely im-
prove completion rates by reducing the bur-
den  on  both  the  patient  and  to  health
infrastructure  itself,  such  as  making  the
DOTS program more manageable and af-
fordable. In contrast to high-income coun-
tries where death from DR-TB is virtually
non-existent, the importance of this technol-
ogy in reducing treatment burden in low-in-
come  countries  cannot  be  overstated:
DR-TB is a death sentence to people in these
communities. Moreover, DR-TB is often al-
lowed to run unchecked throughout these re-
gions, perpetuating a deadly and worsening
cycle of drug resistance. By using readily
available technology, nanoparticle delivery
of ATDs provides a logical, cheap, and at-
tractive solution.
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